Home›Lamivudine And Tenofovir Disoproxil Fumarate

Lamivudine And Tenofovir Disoproxil Fumarate

Also known as: Cimduo

Hepatitis B Virus Nucleoside Analog Reverse Transcriptase InhibitorHuman Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase InhibitorNucleoside Reverse Transcriptase Inhibitors

Route: Oral

Check Lamivudine And Tenofovir Disoproxil Fumarate Interactions →
18 interactions on record⛔ Black Box Warning

Lamivudine And Tenofovir Disoproxil Fumarate has 18 known drug interactions based on U.S. FDA drug labeling data. 5 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Atazanavir, Darunavir, Ledipasvir And Sofosbuvir. Patients taking Lamivudine And Tenofovir Disoproxil Fumarate should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total
18
Major
5
Moderate
13

Major (5)

Moderate (13)

Lamivudine And Tenofovir Disoproxil Fumarate + Tenofovir⚠️Major

( 7.2 ) • HIV-1 Protease Inhibitors: Monitor for evidence of tenofovir toxicity when CIMDUO is coadministrated with atazanavir/ritonavir, darunavir/ritonavir, or lopinavir/ritonavir. ( 7.2 ) • Sorbitol: Avoid chronic administration of sorbitol with CIMDUO.( 7.5 ) 7.1 Drugs Affecting Renal Function Since tenofovir is primarily eliminated by the kidneys [see Clinical Pharmacology (12.3) ] , coadministration of CIMDUO with drugs that reduce renal function or compete for active tubular secretion may increase serum concentrations of tenofovir and/or increase the concentrations of other renally eliminated drugs. Lopinavir/ritonavir, atazanavir coadministered with ritonavir, and darunavir coadministered with ritonavir have been shown to increase tenofovir concentrations [see Clinical Pharmacology (12.3) ] .

Lamivudine And Tenofovir Disoproxil Fumarate + Ledipasvir🟡Moderate

7.3 Hepatitis C Antiviral Agents Coadministration of TDF, a component of CIMDUO, and EPCLUSA ® (sofosbuvir/velpatasvir) or HARVONI ® (ledipasvir/sofosbuvir) has been shown to increase tenofovir exposure [see Clinical Pharmacology (12.3) ] . In patients receiving CIMDUO concomitantly with ledipasvir/sofosbuvir without an HIV-1 protease inhibitor/ritonavir or an HIV-1 protease inhibitor/cobicistat combination, monitor for adverse reactions associated with tenofovir. In patients receiving CIMDUO concomitantly with ledipasvir/sofosbuvir and an HIV-1 protease inhibitor/ritonavir or an HIV-1 protease inhibitor/cobicistat combination, consider an alternative HCV or antiretroviral therapy, as the safety of increased tenofovir concentrations in this setting has not been established.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.